



ERAGEN
BIOSCIENCES
918 Deming Way Madison, WI 53717

For Immediate Release

EraGen Biosciences Announces Luminex License and Distribution Agreement

4/26/07

MADISON, Wis. – EraGen Biosciences, a rapidly growing molecular diagnostics company driving early, accurate diagnosis for disease, announced today it has signed an expanded licensing and distribution agreement with Luminex Corporation, (Nasdaq: LMNX), Austin, Texas.

“Our MultiCode-PLx product line, built on the Luminex® 100 system, a laser-based fluorescent analytical test system, is one of the premier methods for the multiplexed detection of nucleic acids for clinical and research diagnostics. Our technology, in conjunction with the Luminex xMAP® technology creates the fastest and easiest way for CLIA laboratories, hospitals and universities to do automated, multiplexed detection in a one-well assay,” said Irene Hrusovsky, President and CEO of EraGen Biosciences.

Under the terms of the agreement, EraGen has the rights to distribute and sell Luminex 100 Systems and kits that include non-standard nucleic acid bases, proprietary to EraGen, designed for selected in vitro clinical diagnostic purposes.

“We believe the combination of EraGen’s proprietary chemistry and Luminex’s xMAP multiplex technology will be highly competitive in the diagnostics marketplace, particularly against monoplex alternatives,” said Greg Gosch, Luminex Vice President of Marketing. “We look forward to continuing work with EraGen, a Gold sponsor at Luminex’s annual Planet xMAP users meeting this week in Austin, on commercialization of their upcoming product lines.”

The EraGen MultiCode-PLx System is a bead-based nucleic acid detection method that uses PCR in combination with target-specific primers to detect multiple targets in one well. The EraGen test delivers accurate results in hours eliminating tedious steps versus other methods which can take a week or more.

About EraGen Biosciences

Based in Madison, Wisconsin, EraGen Biosciences is driving innovative molecular diagnostics and drugs to market faster. The company develops and commercializes high-performance automated molecular diagnostics and drug discovery products to serve the rapidly growing market for personalized medicine and rapid response needs for bioterrorism.

For additional information contact:

Bonnie Farber

Sales & Marketing Specialist

(608) 662-9000 ext. 344

bfarber@eragen.com